📊 GKOS Key Takeaways
Is GKOS a Good Investment? Thesis Analysis
GLAUKOS demonstrates strong 32% revenue growth and healthy 55.7% gross margins, indicating market demand and product pricing power. However, the company is deeply unprofitable with -39.3% operating margins, negative free cash flow of -$22.5M, and deteriorating diluted EPS (-18.4% YoY). Despite an adequate balance sheet, operational losses are unsustainable and the company is burning cash despite revenue expansion, signaling execution challenges in converting top-line growth into profitability.
Glaukos shows robust revenue growth and solid gross margins, but continues to post sizable operating and net losses with negative free cash flow. A strong, low-leverage balance sheet reduces near‑term solvency risk, yet the path to operating leverage remains unproven. Maintain a HOLD pending clear progress toward positive operating cash flow and improving operating margins.
Why Buy GKOS? Key Strengths
- Strong revenue growth of 32.3% YoY demonstrates market adoption
- Excellent gross margin of 55.7% indicates pricing power and product-market fit
- Solid balance sheet with $90.8M cash, minimal debt ($3.0M), and strong liquidity ratios (4.69x current)
- 32% YoY revenue growth indicating strong demand
- Healthy 55.7% gross margin supporting attractive unit economics
- Strong liquidity and minimal leverage (current ratio 4.69x, low debt)
GKOS Investment Risks to Consider
- Severe operating losses of -$199.6M on $507.4M revenue indicate massive operating expense burden
- Negative free cash flow of -$22.5M despite revenue growth shows operational cash generation failure
- Deteriorating profitability metrics with EPS worsening 18.4% YoY suggests cost structure unsustainable
- Negative ROE (-28.6%) and ROA (-21.0%) indicate value destruction from deployed capital
- Persistent operating losses and -39.3% operating margin
- Negative operating and free cash flow may necessitate future capital needs
- Execution risk in scaling while controlling R&D/SG&A to achieve operating leverage
Key Metrics to Watch
- Operating margin trajectory and path to breakeven
- Operating cash flow inflection point relative to revenue growth
- SG&A and R&D expense as percentage of revenue
- Quarterly cash burn rate and runway analysis
- Operating cash flow trend toward positive
- Operating margin improvement (opex as % of revenue)
GKOS Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.69x current ratio provides a solid financial cushion.
GKOS Profitability Ratios
GKOS vs Healthcare Sector
How GLAUKOS Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GKOS Overvalued or Undervalued?
Based on fundamental analysis, GLAUKOS Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GKOS Balance Sheet & Liquidity
GKOS 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: GLAUKOS Corp's revenue has grown significantly by 73% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.78 indicates the company is currently unprofitable.
GKOS Growth Metrics (YoY)
GKOS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $96.7M | -$16.2M | $-0.28 |
| Q2 2025 | $95.7M | -$19.7M | $-0.34 |
| Q1 2025 | $85.6M | -$18.1M | $-0.32 |
| Q3 2024 | $78.0M | -$21.4M | $-0.39 |
| Q2 2024 | $80.4M | -$32.8M | $-0.68 |
| Q1 2024 | $73.9M | -$34.6M | $-0.72 |
| Q3 2023 | $71.3M | -$27.6M | $-0.58 |
| Q2 2023 | $72.7M | -$32.8M | $-0.68 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GKOS Capital Allocation
GKOS SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for GLAUKOS Corp (CIK: 0001192448)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 3, 2026 | 4 | xslF345X06/form4-04042026_010452.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/form4-04042026_010409.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/form4-04042026_010442.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/form4-04042026_010454.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_110402.xml | View → |
❓ Frequently Asked Questions about GKOS
What is the AI rating for GKOS?
GLAUKOS Corp (GKOS) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 68% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GKOS's key strengths?
Claude: Strong revenue growth of 32.3% YoY demonstrates market adoption. Excellent gross margin of 55.7% indicates pricing power and product-market fit. ChatGPT: 32% YoY revenue growth indicating strong demand. Healthy 55.7% gross margin supporting attractive unit economics.
What are the risks of investing in GKOS?
Claude: Severe operating losses of -$199.6M on $507.4M revenue indicate massive operating expense burden. Negative free cash flow of -$22.5M despite revenue growth shows operational cash generation failure. ChatGPT: Persistent operating losses and -39.3% operating margin. Negative operating and free cash flow may necessitate future capital needs.
What is GKOS's revenue and growth?
GLAUKOS Corp reported revenue of $507.4M.
Does GKOS pay dividends?
GLAUKOS Corp does not currently pay dividends.
Where can I find GKOS SEC filings?
Official SEC filings for GLAUKOS Corp (CIK: 0001192448) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GKOS's EPS?
GLAUKOS Corp has a diluted EPS of $-3.28.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GKOS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, GLAUKOS Corp has a SELL rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GKOS stock overvalued or undervalued?
Valuation metrics for GKOS: ROE of -28.6% (sector avg: 15%), net margin of -37.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GKOS stock in 2026?
Our dual AI analysis gives GLAUKOS Corp a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GKOS's free cash flow?
GLAUKOS Corp's operating cash flow is $-14.8M, with capital expenditures of $7.7M. FCF margin is -4.4%.
How does GKOS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -37.0% (avg: 12%), ROE -28.6% (avg: 15%), current ratio 4.69 (avg: 2).